{
    "clinical_study": {
        "@rank": "114162", 
        "arm_group": [
            {
                "arm_group_label": "Prucalopride", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PEG 3350", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the different effects of prucalopride and PEG 3350 + electrolytes on colon motor\n      activity in subjects that are chronically constipated."
        }, 
        "brief_title": "Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic constipation\n\n          -  Male or female ages 18-75 years\n\n          -  Non-pregnant, non-lactating female\n\n        Exclusion Criteria:\n\n          -  Drug-induced constipation\n\n          -  Subjects suffering from secondary causes of chronic constipation, such as:\n\n               -  Endocrine disorders, e.g. hypopituitarism, hypothyroidism, hypercalcemia,\n                  pseudohypoparathyroidism, pheochromocytoma or glucagon-producing tumors, unless\n                  these are controlled by appropriate medical therapy.\n\n               -  Metabolic disorders, e.g. porphyria, uremia, hypokalemia or amyloid neuropathy,\n                  unless these are controlled by appropriate medical therapy\n\n               -  Neurological disorders, e.g. Parkinson's disease, cerebral tumors,\n                  cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis,\n                  hypoganglionosis, hyperganglionosis, autonomic neuropathy or neuropathy due to\n                  chemotherapy, spinal cord injury, Chaga's disease, or major depression\n\n               -  Surgery.\n\n          -  Subjects with insulin-dependent diabetes mellitus\n\n          -  Rectal evacuation disorder/outlet obstruction\n\n          -  Subjects with intestinal perforation or obstruction\n\n          -  Severe renal impairment\n\n          -  Subjects with a history of alcohol or drug abuse\n\n          -  Subjects with lactose intolerance\n\n          -  Subjects with clinically significant cardiac, vascular, liver, pulmonary, endocrine,\n             neurological or psychiatric disorders"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707667", 
            "org_study_id": "SPD555-403"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prucalopride", 
                "description": "One 2 mg tablet orally administered on Day 1", 
                "intervention_name": "prucalopride", 
                "intervention_type": "Drug", 
                "other_name": "Resolor (Marketed name in Europe)"
            }, 
            {
                "arm_group_label": "PEG 3350", 
                "description": "13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water.  Administered twice orally on Day 1(once in the morning and once prior to lunch).", 
                "intervention_name": "PEG 3350", 
                "intervention_type": "Drug", 
                "other_name": "Movicol"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Oklahoma Foundation for Digestive Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "UNIVERSITY OF LEUVEN, UNVERSITY HOSPITAL, Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Whitechapel, London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Barts Health NHS Trust"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation", 
        "overall_official": {
            "affiliation": "University of Leuven, University Hospital, Department of Gastroenterology, Belgium", 
            "last_name": "Jan Tack, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The Number of High-Amplitude Propagating Contractions (HAPC)", 
            "safety_issue": "No", 
            "time_frame": "over 12 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Concentration Curve (AUC) for Prucalopride", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "The Amplitude of HAPC", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Number and consistency of bowel movements as assessed by the Bristol Stool Scale", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Time Between Occurrence of Bowel Movement and Last HAPC Preceding that Bowel Movement", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Time to first HAPC", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Time to First Bowel Movement", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Propagation Velocity of HAPC", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Duration of HAPC", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }, 
            {
                "measure": "Motility Index", 
                "safety_issue": "No", 
                "time_frame": "over 12 hours post-dose"
            }
        ], 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}